Skip to main content
MediPharm Labs Corp. logo

MediPharm Labs Corp. — Investor Relations & Filings

Ticker · LABS LEI · 875500SIGS9KXW34K754 TSX Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2022-08-15 Regulatory Filings
Country CA Canada
Listing TSX LABS

About MediPharm Labs Corp.

https://medipharmlabs.com/

MediPharm Labs Corp. is a full-service pharmaceutical company specializing in the development, formulation, processing, packaging, and distribution of precision-based, advanced cannabinoid products. Operating from Good Manufacturing Practices (GMP) certified facilities, the company focuses on producing pharma-quality cannabis Active Pharmaceutical Ingredients (API), concentrates, and derivative products. Utilizing strict manufacturing standards and ISO standard cleanrooms, MediPharm Labs ensures its offerings are pure, trusted, and precisely dosable for patients and consumers. Services include wholesale and white label platforms for domestic and international clients. The company holds a Pharmaceutical Drug Establishment License, enabling the manufacture of pharmaceutical drugs containing cannabis.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2022-08-15 English
News release - English.pdf
Earnings Release Classification · 95% confidence The document is a press release announcing the date when MediPharm Labs will report its second quarter 2022 financial results and the details of the upcoming conference call and webcast. It does not contain the actual financial results or substantive financial data but rather informs investors about the timing and logistics of the earnings release and conference call. This fits the definition of an Earnings Release (ER) announcement, as it is the initial announcement of quarterly financial results (key highlights only) and the scheduling of the related call. The document length is about 5306 characters, which is consistent with a typical earnings release announcement. Therefore, the correct classification is ER with high confidence.
2022-08-11 English
News release - English.pdf
Legal Proceedings Report Classification · 95% confidence The document is a news release announcing that MediPharm Labs has been awarded a payment of $9.8 million following a court judgment related to a 2020 statement of claim against a previous customer. It includes management commentary on the impact of this judgment on the company's financial position and potential M&A opportunities. The document does not contain any financial statements, detailed financial performance data, or regulatory filings. It is primarily an update on a legal proceeding outcome and its financial implications, rather than a formal legal proceedings report or a financial report. Given the nature of the content as a corporate announcement about a legal judgment and its financial impact, the most appropriate classification is Legal Proceedings Report (LTR).
2022-07-27 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by MediPharm Labs Corp. It details a material change event, specifically the sale of a subsidiary (MediPharm Labs Australia Pty Ltd) through a Share Purchase Agreement. The document includes a news release about the transaction, management commentary, and forward-looking statements. It is a regulatory filing reporting a material change event rather than a financial report, earnings release, or management discussion. The form number 51-102F3 is a Canadian regulatory form used for material change reports, which fits under the category of Regulatory Filings (RNS). The document is not an announcement of a report publication but the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-07-12 English
Other securityholders documents - English.pdf
Share Issue/Capital Change Classification · 100% confidence The document is titled 'OMNIBUS EQUITY INCENTIVE PLAN' and contains detailed articles and sections about the purpose, definitions, administration, and terms of equity awards such as options, restricted share units, performance share units, and deferred share units. It is a comprehensive plan document outlining the terms and conditions for equity incentives granted to directors, employees, and consultants. There is no indication that this is an announcement or summary; rather, it is the full text of the equity incentive plan itself. This type of document is related to share issue and capital changes as it governs the issuance and management of equity awards. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief announcement or a regulatory filing but the actual plan document.
2022-07-08 English
News release - English.pdf
Regulatory Filings
2022-05-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.